Resectable Oesophageal Cancer: A Practice Guideline Update. Practice Changing or Supporting the Status Quo?

Clinical Oncology

Volumn 22, Issue 4, 2010, Pages 247-249

  Crosby, T D L ^a   Evans, M ^a  

^a VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; EVIDENCE BASED MEDICINE; HUMAN; LYMPHADENECTOMY; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; HUMANS; PRACTICE GUIDELINES AS TOPIC; SURVIVAL RATE;

EID: 77951880201     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2009.08.008     Document Type: Editorial

References (14)

1. Malthaner R., Wong R., Rumble R.B., Zuraw L. Gastrointestinal cancer disease site group. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004, 2:35.
2. Malthaner R., Wong R., Rumble R.B., Zuraw L. Gastrointestinal Cancer Disease Site Group. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline. BMC Cancer 2004, 4:67.
3. Browman G.P., Levine M.N., Mohide E.A., et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995, 13:502-512.
4. Gebski V., Burmeister B., Smithers B.M., et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007, 8:226-234.
5. Thirion P.G., Michiels S., Le Maître A., et al. Individual patient data-based metaanalysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. J Clin Oncol 2007, 25(18S):4512.
6. Blazeby J., Farndon J., Donovan J., Alderson D. A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma. Cancer 2000 Apr, 88(8):1781-1787.
7. Stahl M., Walz M.K., Stuschke M., et al. Preoperative chemotherapy (CTX) versus preoperative chemoradiotherapy (CRTX) in locally advanced esophagogastric adenocarcinomas: First results of a randomized phase III trial. J Clin Oncol 2007, 25(18S):4511.
8. Walsh T.N., Noonan N., Hollywood D., Kelly A., Keeling N., Hennessy T.P.J. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996, 335:462-467.
9. Tepper J.E., Krasna M., Neidzwiecki D., et al. Superiority of trimodality therapy to surgery alone in esophageal cancer: results of CALGB 9781 [abstract]. J Clin Oncol 2006, 24(Suppl 18):A4012.
10. Kelsen D.P., Ginsberg R., Pajak T.F., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998, 339:1979-1984.
11. Medical Research Council Oesophageal Cancer Working Party Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet 2002, 359:1727-1733.
12. Urschel J.D., Vascan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003, 185:538-543.
13. Nutt M., Barham C.P., Falk S., et al. Increased mortality rate after oesophagectomy in patients receiving neoadjuvant treatment. Br J Surg 2002, 89:375-382.
14. MRC OE05: perioperative chemotherapy in patients with oesophageal adenocarcinoma. http://www.ctu.mrc.ac.uk/studies/OE05.asp.